These findings may be consistent with the fact that although RCTs of SGLT2 inhibitors reported decreased cardiovascular events [6, 7], these treatments did not reduce atherothrombotic events such as myocardial infarction and stroke [6, 7, 26]. The gene discussed is SLC5A2; the disease is myocardial infarction.